At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD, from Dana-Farber Cancer Institute, Boston, MA, discusses the application of the concept “oncogene addiction”, which postulates that a cancer cell exhibits dependence on a single oncogenic pathway or protein for its sustained proliferation or survival, in the development of targeted therapies for non-small cell lung cancer (NSCLC).
Oncogene-addicted non-small cell lung cancer
4th February 2016
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?